Table 4 Reference point dose difference between pre- and post-CE, compared with the average change of effective depth
From: Dosimetric effect of CT contrast agent in CyberKnife treatment plans
Case No. | Target | Mean deffdifference | Reference point dose | |
|---|---|---|---|---|
In RT | In MC | |||
1 | Lung (Left Lower Lobe) | 11.4 mm | 6.2% | 3.8% |
2 | Lt. Pleura | 11.0 mm | 5.7% | 4.0% |
3 | Lung (Left Upper Lobe) | 7.4 mm | 3.3% | 2.4% |
4 | T4 | 6.4 mm | 2.7% | 3.8% |
5 | Liver (Segment 6) | 4.7 mm | 2.7% | 3.0% |
6 | PAN* | 5.2 mm | 2.4% | 0.2% |
7 | Lung (Left Upper Lobe) | 4.1 mm | 2.1% | 1.7% |
8 | L2 | 3.9 mm | 2.1% | 1.9% |
9 | SMA LN†| 3.7 mm | 1.9% | 1.7% |
10 | Liver (Segment 8) | 3.2 mm | 1.6% | 1.1% |
11 | T1-2‡ | 3.1 mm | 1.5% | 1.0% |
12 | L2-5§ | 3.6 mm | 1.3% | 2.1% |
13 | Lung (Right Middle Lobe) | 2.6 mm | 1.2% | 1.3% |
14 | Iliac LN | 2.0 mm | 1.1% | 0.6% |
15 | Lt. Kidney (Renal Pelvis) | 4.4 mm | 1.0% | 1.2% |
16 | Prostate | 1.2 mm | 0.8% | 1.1% |
17 | C5|| | 1.5 mm | 0.7% | 1.1% |
18 | C5-T2 | 3.1 mm | 0.6% | 0.5% |
19 | Prostate | 1.2 mm | 0.6% | 0.7% |
20 | Prostate | 1.6 mm | 0.6% | 1.1% |
21 | Prostate | 1.1 mm | 0.5% | 0.4% |
22 | Prostate | 1.1 mm | 0.4% | 0.9% |
|  | Average ± 1SD | 4.0 ± 2.9 mm | 1.9 ± 1.6% | 1.6 ± 1.1% |